Welcome to our dedicated page for Neurobo Pharmaceuticals SEC filings (Ticker: NRBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NRBO SEC filings page aggregates the regulatory history of NeuroBo Pharmaceuticals, Inc., which has transitioned to MetaVia Inc., a clinical-stage biotechnology company focused on cardiometabolic diseases. Through these filings, investors can trace how the company reports its progress on DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH), along with key corporate actions.
Recent Forms 8-K filed under the MetaVia Inc. name document material events such as press releases on clinical trial developments for DA-1726, including extensions of multiple ascending dose cohorts, and collaborations to optimize DA-1241 using artificial intelligence–driven drug discovery. Other 8-K filings describe financial results releases and updated corporate presentations, providing insight into the company’s operating progress and communication with the market.
Filings also capture corporate governance and capital structure decisions. For example, an 8-K describing the annual meeting of stockholders details votes on director elections, ratification of the independent registered public accounting firm, advisory approval of executive compensation, authorization of a reverse stock split within a specified ratio range, and approval of share issuances related to financing arrangements.
On Stock Titan, these SEC documents are available with AI-powered summaries that explain the key points of each filing in accessible language. Users can quickly understand the implications of MetaVia’s current reports, including 8-K disclosures on clinical, financial, and governance matters, and navigate the historical record associated with the NRBO ticker as the company continues under the MetaVia identity.
MetaVia Inc. Reporting persons Armistice Capital, LLC and Steven Boyd disclose beneficial ownership of 1,270,887 shares of MetaVia common stock, representing 4.99% of the class. Armistice Capital is the investment manager to Armistice Capital Master Fund Ltd., the direct holder, and exercises shared voting and dispositive power over the shares reported. Mr. Boyd, as managing member of Armistice Capital, is also reported as having shared voting and dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Woodworth Marshall H, listed as Chief Financial Officer, reported a Form 4 for MetaVia Inc. (MTVA) showing a transaction dated 08/12/2025. The filing records a transaction code G and shows acquisition of 14,200 shares at a price of $0, bringing his beneficial ownership to 30,079 shares. The Form 4 was executed by a power of attorney on 08/13/2025 and includes Exhibit 24 (Power of Attorney).
MetaVia Inc. Form 8-K — Regulation FD disclosure (Aug 6, 2025)
MetaVia furnished a press release announcing an extension of the 48 mg multiple ascending dose (MAD) cohort in the Phase 1 clinical trial of DA-1726 from 4 weeks to 8 weeks and reporting that a fifth weekly dose was administered to the first patient. DA-1726 is described as a novel dual oxyntomodulin (OXM) analog agonist acting at GLP1R and GCGR for obesity treatment.
- Date: August 6, 2025
- Action: Cohort duration extended to 8 weeks (from 4 weeks)
- Dosing update: Fifth weekly dose given to first patient
- Exhibit: Press release furnished as Exhibit 99.1 (information furnished, not filed)
FAQ
What is the current stock price of Neurobo Pharmaceuticals (NRBO)?
What is the market cap of Neurobo Pharmaceuticals (NRBO)?
